Stated another way, it’s probably correct that we’ll have a brief stall around $15. But that’s predominantly a psychological hurdle only. Fundamentally, that level should act more as a floor than a ceiling. People who just bought in at $15 aren’t selling below that.
One potential headwind to accelerated revenue growth (not just CW, all CBD companies) is that major retailers are only carrying topical products. To my knowledge, few of the larger retailers have been willing to take on tinctures and capsules (CWBHF's bread and butter) due to regulatory risk with the FDA.